FDA grants accelerated approval to COLUMVI (glofitamab-gxbm) for the treatment of adult patients with selected relapsed or refractory large B-cell lymphomas

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf?utm_medium=email&utm_source=govdelivery